Day 1Tuesday, September 1, 2026 - UTC+08:00

• Demonstrating Abogen's unique mRNA and LNP platform
• Sharing clinical data and progress of mRNA cancer vaccines
• Accelerating preclinical and clinical development of mRNA-based T cell engagers and in vivo CAR-T

Resistant cancers survive by deploying RNA strategies that regulate translation and stability, thereby modulating tumor persistence and immune signaling. By decoding these adaptive RNA programs, we can harness or modulate these regulatory circuits to control tumor adaptation and reduce the emergence of new resistance mechanisms. Leveraging multi-omic profiling and AI-guided modeling, this approach transforms stress-responsive RNA programs into programmable RNA therapeutics, including inducible translation circuits and targeted RNA modulators. Through this framework, RNA therapeutics can dynamically respond to tumor stress—enhancing resilience, precision, and adaptability—while exploiting the same code-control mechanisms tumors use to survive.

• Adaptive RNA Programs: Resistant tumors rewire coding and noncoding RNA programs to regulate translation and stability, enabling therapeutic persistence and immune evasion. These adaptive circuits can be therapeutically harnessed or modulated to control tumor persistence.
• Programmable RNA Therapeutics: By integrating multi-omic data and AI-guided modeling, stress-responsive translation circuits can be designed as programmable RNA therapeutics that dynamically respond to tumor adaptation, control protein output, and reduce the emergence of new resistance mechanisms.